X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/destiny-calls-time-sporegen-covid-collab-while-santhera-hands-lonodelestat-back-spexis
https://www.pharmiweb.com/press-release/2023-05-02/destiny-pharma-and-sporegen-announce-update-from-research-collaboration-under-innovate-uk-grant-award-to-develop-a-biotherapeutic-treatment-spor-cov-for-covid-19-and-influenza
https://endpts.com/uk-biotech-hands-off-mid-stage-c-difficile-drug-in-up-to-570m-deal/
https://www.fiercebiotech.com/biotech/destiny-seals-c-diff-therapys-phase-3-fate-sebela
https://www.proactiveinvestors.co.uk/companies/news/944950/destiny-pharma-targets-growth-as-anti-infection-treatments-return-to-prominence-944950.html
https://www.voxmarkets.co.uk/rns/announcement/e7e0acd1-63dd-400d-a4dc-4ce5a6833f02/
https://www.stockmarketwire.com/article/7217018/Destiny-Pharma-announces-expansion-of-clinical-pipeline-in-China.html
https://www.marketscreener.com/quote/stock/DESTINY-PHARMA-PLC-37788317/news/Destiny-Pharma-nbsp-06-July-2021-ndash-NTCD-M3-RD-Agreement-with-US-Dept-Veterans-Affairs-35795114/
https://www.destinypharma.com/2021/06/10/10-june-2021-xf-73-data-abstract-to-be-presented-at-2021-eccmid/amp/
https://www.businesswire.com/news/home/20210406005251/en/DESTINY-CRC02-Phase-2-Trial-of-ENHERTU%C2%AE-Initiated-in-Patients-with-HER2-Overexpressing-Advanced-Colorectal-Cancer
Market Place
Share 
